YIDU TECH(02158): Affiliated company wins bid for the construction project of the intelligent clinical research integration platform of Tianjin Cancer Hospital.
Yidu Technology (02158) announced that its affiliated company Yidu Cloud (Beijing) Technology Co., Ltd. recently won the bid for the project to construct an intelligent clinical research integration platform at Tianjin Cancer Hospital. The total amount of the project is approximately 7.39 million RMB.
YIDU TECH (02158) announced recently that its affiliated company Yidu Cloud (Beijing) Technology Co., Ltd. has won the bid for the construction project of an intelligent clinical research integrated platform at Tianjin Cancer Hospital. The total amount of the project is approximately 7.39 million RMB.
YIDU TECH is the core force driving the intelligent upgrade of China's medical system. The company empowers the whole chain of "medicine, health insurance, and patients" with intelligent decision-making, aiming to make precision medicine accessible to everyone. By simulating the clinical decision-making logic of doctors, training on real disease development processes, and repeatedly verifying in the real world, the company has created "AI that truly understands diseases." It provides measurable value for key links in the medical ecosystem: empowering doctors with more precise and efficient decision-making tools, helping pharmaceutical companies shorten the distance from molecules to patients, enabling patients to afford precise diagnosis and treatment, and providing more scientific support to the public healthcare system. YIDU TECH, with its independently innovative system-level intelligence, is creating a more resilient, caring, inclusive, and efficient future for healthcare.
Related Articles

YIDU TECH (02158) wins a bid for a 7.39 million yuan AI medical order. Recently, it has been awarded multiple top medical institution projects.

ZXZN QI-HOUSE (08395) suspended trading briefly in the afternoon of May 21st.

GRAND PHARMA (00512) nuclear medicine partner Telix innovative product TLX101 for the treatment of newly diagnosed primary glioblastoma overseas phase I study made a key progress setting a new benchmark for global brain cancer treatment.
YIDU TECH (02158) wins a bid for a 7.39 million yuan AI medical order. Recently, it has been awarded multiple top medical institution projects.

ZXZN QI-HOUSE (08395) suspended trading briefly in the afternoon of May 21st.

GRAND PHARMA (00512) nuclear medicine partner Telix innovative product TLX101 for the treatment of newly diagnosed primary glioblastoma overseas phase I study made a key progress setting a new benchmark for global brain cancer treatment.






